Medicines: Apply for a Parallel Import License

9 December 2022 – the MHRA published updated guidance on applying for a parallel import license.

The UK parallel import licensing scheme lets a medicine authorized in a European Economic Area (EEA) Member State be marketed in the UK, as long as the imported product has no therapeutic difference from the cross-referenced UK product.

The MR-DC product list in the section “Make a TaD variation” has been updated.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /